Compare Eli Lilly And Co (LLY) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.27 (market cap $28.69M). The key difference: Eli Lilly And Co is far larger — about 36249.6× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days on average.
| LLY | QDTY | |
|---|---|---|
Market Cap | $1.04T | $28.69M |
Volume | 3,064,878 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.28K | $46.71 |
52-Week Low | $799.57 | $36.57 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
QDTY trades at $39.27, down 0.84% today, with a bullish technical signal supported by moving averages. The ETF demonstrates strong dividend distribution activity with recent payouts ranging from $0.19 to $0.30 per share, highlighted by a $0.24 dividend announced October 6th, 2026 representing a significant yield. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while overall trend remains positive.
The outlook remains favorable for income-focused investors given the consistent dividend payments, though elevated RSI levels suggest near-term caution. Key risks include market volatility affecting covered call strategies and interest rate sensitivity. The ETF's weekly distribution model provides regular income but requires monitoring of underlying Nasdaq 100 performance for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
